924473-59-6

中文名稱 T5601640

英文名稱 T5601640

CAS 924473-59-6

分子式 C19H14F3N3O3

分子量 389.33

MOL 文件 924473-59-6.mol

更新日期 2026/06/02 12:03:27

924473-59-6 結構式

基本信息物理化學性質安全數(shù)據(jù) 圖譜信息 T5601640價格(試劑級) 常見問題列表

基本信息

中文別名

化合物T56-LIMKI
LIMK2抑制劑(T56-LIMKI)

英文別名

T5601640
T56-LIMKi
T-5601640(T56-LIMKi)
T56-LIMKi - T5601640
T5601640
T 5601640
T56-LIMKI
3-methyl-N-[3-[[3-(trifluoromethyl)phenyl]carbamoyl]phenyl]-1,2-oxazole-5-carboxamide
3-Methyl-N-[3-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]-5-isoxazolecarboxamide
5-Isoxazolecarboxamide, 3-methyl-N-[3-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]-

所屬類別

生物化工：激動劑抑制劑

物理化學性質

沸點403.4±45.0 °C(Predicted)

密度1.426±0.06 g/cm3(Predicted)

儲存條件2-8°C

溶解度DMF: 30 mg/ml; DMF:PBS(pH7.2) (1:2): 0.33 mg/ml; DMSO: 20 mg/ml

酸度系數(shù)(pKa)11.41±0.70(Predicted)

形態(tài)粉末

顏色白色至米色

InChI1S/C19H14F3N3O3/c1-11-8-16(28-25-11)18(27)24-14-6-2-4-12(9-14)17(26)23-15-7-3-5-13(10-15)19(20,21)22/h2-10H,1H3,(H,23,26)(H,24,27)

InChIKeyXVOKFRPKSAWELK-UHFFFAOYSA-N

SMILESO=C(NC1=CC(C(F)(F)F)=CC=C1)C2=CC(NC(C3=CC(C)=NO3)=O)=CC=C2

安全數(shù)據(jù)

危險性符號(GHS) 有毒 (GHS06)

GHS06

警示詞危險

危險性描述H301-H413

防范說明P273-P301+P310+P330

危險品運輸編號UN 2811 6.1 / PGIII

WGK GermanyWGK 3

存儲類別6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects

危險性類別Acute Tox. 3 Oral
Aquatic Chronic 4

圖譜信息

T5601640(924473-59-6)核磁圖(¹HNMR)

T5601640價格(試劑級)

報價日期	產品編號	產品名稱	CAS號	包裝	價格
2026/03/03	S6498	T5601640 T56-LIMKi	924473-59-6	5mg	958.41元
2025/12/22	HY-19352	T5601640 T56-LIMKi	924473-59-6	1 mg	233元
2025/12/22	HY-19352	T5601640 T56-LIMKi	924473-59-6	10mM * 1mLin DMSO	428元

常見問題列表

生物活性

T56-LIMKi是LIM kinase 2 (LIMK2)抑制劑，抑制LIMK2介導的絲切蛋白磷酸化。

靶點

Target	Value
LIMK2 ()

體外研究

T56-LIMKi efficiently inhibits the growth of ST88-14, U87, Panc-1 cells, A549 lung cancer cells with IC ₅₀ values of 18.3, 7.4, 35.2 and 90 μM, respectively. T56-LIMKi decreases phosphorylated cofilin (p-cofilin) levels and thus inhibits growth of several cancerous cell lines, including those of pancreatic cancer, glioma and schwannoma. It blocks the phosphorylation of cofilin which leads to actin severance and inhibition of tumor cell migration, tumor cell growth, and anchorage-independent colony formation in soft agar. T56-LIMKi (10-50 μM) reduces p-cofilin in a dose-dependent manner in NF1 ^?/? MEFs with an IC ₅₀ of 30 μM. Notably, the inhibitor does not affect the amounts of total cofil. 50μM T56-LIMKi causes a statistically significant reduction in the number of cells exhibiting stress fibers.

體內研究

T56-LIMKi can induce inhibition of cofilin phosphorylation and Panc-1 tumor shrinkage in vivo . Mice treated with T56-LIMKi (60 mg/kg) shows a significant decrease in tumor volume compared to control.